Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-NeoB in Newly Diagnosed and Recurrent Glioblastoma
NCT05739942Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2024
- Primary completion
- Aug 2027
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 1, open-label trial of AAA503 in glioblastoma (GBM) (2 arms), sponsored by Novartis. Primary endpoint: Dose Limiting Toxicity. Started May 2024; status: active, not recruiting.
02
Drugs
AAA503
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05739942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739942.